ArticleBMC cancer2026
A novel diagnostic model combining ProGRP and inflammatory biomarkers for early detection of lung cancer: development and validation in treatment-naive cohorts.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung cancer remains the leading cause of cancer-related mortality globally, with late-stage diagnosis contributing to poor outcomes. Non-invasive biomarkers capable of complementing existing screening modalities are urgently needed to improve early detection.
methodsThis retrospective study developed and validated a diagnostic model using serum tumor markers and inflammation-related biomarkers. The training cohort included 110 treatment-naive lung cancer patients and 107 healthy controls, while an external validation cohort comprised 44 lung cancer patients and 52 controls. Compare the differences in tumor markers, cytokines, and indices derived from whole blood cell counts between the lung cancer group and the healthy control group. Logistic regression analysis was used to identify independent risk factors for lung cancer and to construct a clinical prediction model. The model’s discrimination, calibration, and clinical applicability were assessed using receiver operating characteristic (ROC) curves, the Hosmer-Lemeshow test, and decision curve analysis (DCA), among other methods.
resultsThe predictive model demonstrated high diagnostic accuracy in the training cohort, with an AUC of 0.972 (sensitivity 89.2%, specificity 99.1%). External validation showed an AUC of 0.897 (sensitivity 72.7%, specificity 98.1%), confirming its good generalizability. Notably, Pro-Gastrin Releasing Peptide(ProGRP)and inflammatory markers were independently associated with the risk of lung cancer (P < 0.05). DCA analysis indicated that the model has significant clinical utility across a wide range of probability thresholds (0–80%).
conclusionThis study presents a high-performance, non-invasive diagnostic model integrating ProGRP and systemic inflammatory biomarkers for lung cancer detection. The combined model outperforms individual biomarkers and may enhance early lung cancer screening, particularly in settings where imaging modalities are limited. Further multi-center prospective studies are warranted to validate its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.